This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on June 3, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Development and Validation of an Antibody for Detection of Lysine Homocysteinylation in Cobalamin Disorders

Closed

75N98026Q00506Federal

Submission Closed06/13/2026, 01:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Grant

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)This contract opportunity from the National Institutes of Health under the Department of Health and Human Services aims to support the development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain treatment. It focuses on accelerating early-stage therapeutic candidates through preclinical optimization to readiness for Phase II clinical trials. Eligible applicants must present a promising lead candidate with strong biological justification and established assays to guide optimization. The funded activities include lead optimization, early development, IND-enabling studies, biomarker development, submission of an Investigational New Drug application, and Phase I clinical testing. The program is structured as a milestone-driven, phased cooperative agreement with active NIH involvement in project planning and monitoring. The solicitation is identified as RFA-NS-27-007, titled HEAL Initiative: Non-addictive Analgesic Therapeutics Development, with clinical trials optional. The solicitation was posted on June 16, 2026, and applicants must respond by February 20, 2029. This federal contract emphasizes collaborative advancement of innovative pain therapeutics while ensuring rigorous oversight from NIH program staff throughout the project lifecycle.

National Institutes Of Health

POSTED

DEADLINE

Scientific Data Analysis & Software Tool Development for JWSTThe contract involves the development and ongoing maintenance of software tools specifically designed for the calibration of NIRISS data, pipeline processing, and support of scientific operations related to the James Webb Space Telescope (JWST). This subcontract opportunity, issued by the National Research Council of Canada under the Government of Canada, seeks expertise in scientific data analysis and software tool development to enhance JWST's data handling capabilities. The work is to be performed in British Columbia and is associated with NAICS code 541714, indicating a focus on research and development in the physical, engineering, and life sciences. The solicitation was posted on June 15, 2026, with a response deadline of June 30, 2026. Although specific details such as set-aside types, organization type, or a direct point of contact are not provided, interested parties are encouraged to refer to the official tender notice link for more information. The contract emphasizes advanced software solutions to support scientific missions, ensuring the effective processing and analysis of space telescope data crucial for ongoing research.

National Research Council of Canada

POSTED

DEADLINE

International Agricultural Research Program DesignThe contract entails the design and structuring of a comprehensive international agricultural research program that aligns with the priorities of the Foreign Agricultural Service under the Department of Agriculture. It involves developing clear objectives, detailed methodologies, and expected outcomes aimed at advancing agricultural research on a global scale. The scope emphasizes strategic planning to address international agricultural challenges while supporting USDA-FAS goals to enhance trade, sustainability, and food security. This subcontract, carrying the NAICS code 541714, was posted on June 15, 2026, with a response deadline of August 14, 2026. While specific details such as the location of performance and contact information are not provided, the focus is on crafting a program that integrates scientific research with policy priorities to foster innovation and collaboration in international agriculture. The resulting program is expected to facilitate informed decision-making and promote economic opportunities within the global agricultural sector.

Foreign Agricultural Service

POSTED

DEADLINE

TECHNOLOGY LICENSING OPPORTUNITY: DC RecruiterDC Recruiter is an innovative immune-enhancing technology developed by scientists at Los Alamos National Laboratory that uses a self-assembling peptide nanofiber to recruit and activate dendritic cells, critical components of the immune system. Unlike traditional pathogen-specific vaccines and treatments, this approach is designed to trigger an early, broad-spectrum immune response regardless of the specific infectious agent. The product is formulated as a needle-free, spray-friendly application, enhancing its practicality and ease of use in various settings. Its core advantage lies in addressing the challenge of rapid immune activation before the pathogen is identified, providing fast-acting defense during exposure scenarios where conventional methods may be delayed, too specific, or ineffective. This technology holds promise across multiple market sectors, including infectious disease prevention, outbreak management, national defense, consumer health, pharmaceuticals, and emergency preparedness. Its broad, pathogen-agnostic mechanism makes it especially valuable in high-risk or field environments requiring quick deployment and flexible administration. Currently at a technology readiness level of 3, DC Recruitor is patent-pending and available for licensing through Los Alamos National Laboratory’s program, which facilitates exclusive and non-exclusive licensing agreements to commercial partners seeking to leverage cutting-edge innovations for competitive advantage. The ongoing solicitation invites potential collaborators to engage before the stated deadline.

Triad - DOE Contractor

POSTED

DEADLINE

Contact Activation Pathway Function Blocking Antibody AB023The Defense Health Agency is conducting a Request for Information (RFI) to gather market intelligence and identify qualified sources for the supply of the contact activation pathway function blocking antibody AB023, also known as Xisomab 3G3 or Gruticibart. This antibody is designed to inhibit Coagulation Factor XI (FXI) by targeting the "apple 2" domain, preventing its activation by activated factor XII (FXIIa) in the contact pathway, which is implicated in clot formation on artificial surfaces. The antibody is intended for use in medical applications such as Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-associated thrombosis. It is designed to preserve natural clotting processes by not interfering with FXI activation by thrombin or the conversion of Factor IX by activated FXI, thus maintaining normal hemostasis required for wound healing. The Government anticipates procuring up to 0.5 grams of AB023 annually and requires pharmacokinetic and pharmacodynamic testing to assess its concentration over time, biochemical impacts, clotting time effects, and ability to prevent thrombus growth and fibrin accumulation in vascular thrombosis models. Stability, dosage, and potency validations must be conducted using clotting assays. Although this announcement does not represent a solicitation or obligation to award a contract, interested parties with relevant expertise must submit technical information by June 18, 2026. All responders must be registered in the System for Award Management (SAM). The associated NAICS code is 541714, reflecting research and development in biotechnology. The point of contact is based at the Defense Health Agency in Fort Detrick, Maryland, with the place of performance listed in Texas.

Defense Health Agency

POSTED

5 days ago

DEADLINE

in 1 day

AI Contract Overview

The contract focuses on the development and validation of a novel antibody specifically targeting N-homocysteine-lysine, a post-translational modification currently lacking a commercially available antibody. This initiative aligns with the U.S. Government's efforts to advance biomedical research, particularly in understanding rare genetic diseases and accelerating precision medicine. The project entails synthesizing and purifying peptide antigens containing N-homocysteinylated lysine residues alongside control peptides, conjugating these peptides to carrier proteins, and immunizing rabbits to generate polyclonal antibodies. The generated sera will be tested against laboratory samples to confirm specificity and efficacy through ELISA screening and other assays. Following immunization and antibody production, purification of the working antibody will be performed to facilitate detailed characterization of proteins influenced by this aberrant modification. This research aims to provide insights into disease mechanisms related to cobalamin disorders, with potential applications in developing targeted therapies. The contract is a total small business set-aside issued by the National Institutes of Health, Department of Health and Human Services, with a deadline for response on June 13, 2026, and is located in Bethesda, Maryland.

General Info

Develop novel antibody targeting N-homocysteine-lysine for biomedical research and therapeutic development.

Agency

Department Of Health And Human Services → National Institutes Of Health Olao

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

MD, 20892, USA

Set-Aside

SBA

Documents

(1)

Requirement+rev8.docx

DOCX

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedJun 3

Presolicitation

Response DeadlineJun 13

Deadline has passed

Submission Closed

06/13/2026, 01:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Olao

Office AddressBETHESDA, MD, 20892, USA

Contacts

John Burton

contact@example.gov

Full Description

Requirements:

The proposed development of a novel post-translational modification (PTM)-specific antibody directly supports the U.S. Government's mission to advance biomedical research on rare genetic diseases, improve public health outcomes, and accelerate the development of precision medicine approaches

Currently there is no commercially available antibody against N-homocysteine-lysine (N-homocysteinylation) so we will need to have one generated. By generating it, we are able to provide specifications for the peptide sequence based on preliminary findings in our scientific models of disease insuring it will work effectively. Our objectives are as follows:

Synthesize and purify peptide antigens with N-homocysteinylated lysine residues and matched control peptides with unmodified lysines. Conjugate peptides to carrier proteins (e.g., KLH) for immunization
Immunize appropriate host species (rabbit for polyclonal antibody generation)
Generate polyclonal sera prior to immunization and 2 to 3 times after following antigen boost. Test sera on lab samples of N-homocysteinylated proteins from mouse models of MMACHC delicacy in our lab. Also perform ELISA screening of antibody on modified and unmodified peptide.
Terminal bleed on immunized animal and purification of working antibody from serum
With working antibody we will characterize the proteins affected by this aberrant posttranslational modification to better understand disease development and in future design targeted therapies for it.